Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-02-20 | Reverse | 1:10 |
| 2020-05-11 | Reverse | 1:12 |
Aurora Cannabis Inc. produces, distributes, and develops medical and recreational cannabis products, accessories, and related services globally, including research, breeding, manufacturing, and patient support through various brands and facilities.
Aurora's proprietary, high-THC (27%) medical cannabis cultivar, recently launched in Poland, exemplifies its shift to science-driven, high-margin products in the growing European medical cannabis market.
On June 18, 2025, Aurora Cannabis announced record annual global medical cannabis net revenue of $244.4 million and record adjusted EBITDA of $49.7 million for the fiscal year ending March 31, 2025. Despite these positive annual results, the company's stock dropped significantly, reportedly by over 20%, due to a weaker-than-expected outlook for the upcoming quarter, citing regulatory issues in Poland and higher logistics costs.
Aurora Cannabis Inc. (NASDAQ: ACB - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders acquired 2,710 call options on the stock. This is an increase of approximately 248% compared to the average daily volume of 778 call options. Aurora Cannabis Stock Up 15.2% NASDAQ: ACB traded up $0.59 during trading
Curaleaf Hldgs Inc. (OTCQX:CURLF), the Connecticut-based cannabis company, has raised its offer for Aurora Cannabis Inc (TSX:ACB, NASDAQ:ACB), a Canadian cannabis producer, by 25% to a total implied value of $5 per Aurora share in cash and stock. The new price is 86% above Aurora's 30-day volume-weighted average share price of $2.75 as of August 10, the day before Curaleaf announced its intention to make its initial offer.
ProPhase Labs (NASDAQ: PRPH - Get Free Report) and Aurora Cannabis (NASDAQ: ACB - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability. Institutional and Insider Ownership 9.4% of ProPhase
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
 IRWD | $3.62 | COMPARE |
 ACRS | $4.23 | COMPARE |
 TKNO | $9.01 | COMPARE |
 EDIT | $2.75 | COMPARE |
 CGC | $0.88 | COMPARE |
 LFCR | $6.51 | COMPARE |
 BIOA | $6.48 | COMPARE |
 HITI | $2.71 | COMPARE |
